Skip to content Skip to footer
Hadlima: Benefits, Reviews, Info, Side Effects!
Rx Details
Hadlima
Adalimumab, Humira
Adalimumab
Prescription
Biologic
Supplements
Biosimilar
adalimumab biosimilar, reduces inflammation, treats rheumatoid arthritis, treats psoriatic arthritis, treats ankylosing spondylitis, treats Crohn’s disease, treats ulcerative colitis, treats plaque psoriasis, treats hidradenitis suppurativa, treats uveitis
Abdominal Pain, Back Pain, Dizziness, Elevated Liver Enzymes, Fatigue, Headache, Hypertension, Infections, Injection Site Reactions, Nausea, Rash, Sinusitis, Upper Respiratory Tract Infections, Urinary Tract Infections
Hadlima is a biosimilar to Humira (adalimumab), which is used to treat various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis, among others. The dosage of Hadlima can vary depending on the condition being treated. Here are some general guidelines: 1. **Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis**: The typical dosage is 40 mg administered every other week as a subcutaneous injection. Some patients not taking methotrexate may benefit from increasing the frequency to 40 mg every week. 2. **Crohn’s Disease and Ulcerative Colitis**: The initial dose is usually 160 mg, followed by 80 mg two weeks later, and then 40 mg every other week. 3. **Plaque Psoriasis**: The initial dose is typically 80 mg, followed by 40 mg every other week starting one week after the initial dose. It’s important to note that these are general guidelines and the exact dosage may vary based on individual patient needs, response to treatment, and specific medical advice from a healthcare provider. Always consult with a healthcare professional for the appropriate dosage for your specific condition.
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, uveitis
Safety profile of Hadlima is generally favorable.
No interactions found
$100 – $200
$1,000

A Synopsis of

Hadlima

Hadlima is a biosimilar medication that is used to treat a variety of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting specific proteins in the body that are involved in the inflammatory response, helping to reduce pain, swelling, and stiffness in the joints.

As a medical professional, I often recommend Hadlima to patients who have not responded well to other treatments or who are looking for a more cost-effective option. Biosimilar medications like Hadlima are designed to be highly similar to the original biologic drug, providing a safe and effective alternative for patients.

It is important to discuss with your healthcare provider if Hadlima is the right treatment option for you. They will consider your medical history, current medications, and overall health to determine if this medication is appropriate for your condition.

Like all medications, Hadlima may cause side effects in some patients. These can include injection site reactions, headaches, and infections. It is important to report any unusual symptoms to your healthcare provider so they can monitor your response to the medication and make any necessary adjustments to your treatment plan.

Overall, Hadlima has been shown to be a valuable treatment option for many patients with inflammatory conditions. If you have any questions or concerns about this medication, do not hesitate to reach out to your healthcare provider for more information.

RxDb Legal Disclaimer

The information provided on RxDB.net is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional, such as a doctor or pharmacist, for any questions or concerns regarding your health, medications, or medical conditions. Reliance on any information provided on this website is solely at your own risk. RxDB.net does not provide medical or pharmaceutical services and is not liable for any decisions made based on the information contained herein.

PAGE LAST UPDATED

Health Education Through Aggregation

Sign up for the Rx Database Newsletter!
Menu
Questions?

Website By Foxco © 2025. All rights reserved.

0
Would love your thoughts, please comment.x
()
x
en_USEN